All In Biotech

Drug Trial Radar · NCT05887492

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Jun 12, 2023

Primary completion

Sep 22, 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Tango Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.

Conditions

  • Non Small Cell Lung Cancer
  • Solid Tumors, Adult
  • Lung Cancer
  • Lung Adenocarcinoma

Interventions

  • TNG260Drug

    CoREST inhibitor, administered orally

  • PembrolizumabDrug

    Pembrolizumab, an anti-PD-1 antibody, administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the MTD and RP2D(s) (Phase 1 only)Time frame: 42 days
  2. Measure antitumor activity using RECIST 1.1 (Phase 2 only)Time frame: 12 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Hematology/Oncology

    Santa Monica, California

  • SCRI at HealthOne

    Denver, Colorado

  • Florida Cancer Specialists

    Sarasota, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • START MidWest

    Grand Rapids, Michigan

  • NYU Langone Hematology Oncology Associates-Mineola

    Mineola, New York

  • New York University Langone Health

    New York, New York

  • Sarah Cannon Tennessee Oncology

    Nashville, Tennessee

  • US Oncology Investigational Products Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology Virginia

    Fairfax, Virginia

  • US Oncology Investigational Products Center

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.